BRIDGEWATER, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer, will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023. Management will also be available for 1-on-1 meetings with investors. Presentation Details Company Presentation: Monday, September 11, 2023 at 7:00 AM ET Speaker: David Domzalski, President and Chief Executive Officer Registration: Webcast Link The replay of the webcast will…